Global Sodium Selenite Market, by Indication (Selenium Deficiency, Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 45.2 Million in 2022, and is expected to exhibit a CAGR of 9.3% during the forecast period (2022-2030).
Increasing prevalence of selenium deficiency is expected to drive growth of the market over the forecast period. For instance, according to an article published in Environmental Sciences journal, 2017, selenium deficiency is thought to be rare in the U.S. However an estimated 1 billion people around the world were affected by insufficient selenium intake upto 2016.
Increasing research and development activities of sodium selenite as potential treatment for various diseases is expected to fuel the global sodium selenite market over forecast period. For instance, according to an article published in Journal of Cellular Physiology, September 2018, in China, a number of in-vitro research in mouse syngeneic breast tumor models demonstrated that sodium selenite (SSE) promotes apoptosis via ROS-mediated suppression of NF-B signaling and activation of the Bax-caspase-9-caspase-3 axis, making it a frequently utilized cancer treatment.
Global Sodium Selenite Market - Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic has affected several markets across the globe. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and impacting firms and markets financially.
The impact of COVID-19 on the global sodium selenite Market was significant, owing to its use in sodium selenite treatment. For instance, according to an article published in International Journal of Molecular Sciences, December, 2021, Selenium plays a critical role in the host's defence against viruses like SARS-CoV-2, and selenium deficiency dramatically impairs crucial processes like redox homeostasis, antioxidant stress reduction, and oxidative stress reduction. The decrease in selenium levels in the serum and plasma of individuals with severe COVID-19 suggests that there are probably not enough functioning selenoproteins. Hence, this can be beneficial for drug development manufacturers and COVID-19 researchers to help in developing selenium-based treatments.